{"entity":{"id":"nct06561685","kind":"trial","name":"A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1 trial of FHD-909 run by Eli Lilly and Company, now recruiting.","summary":"A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors is a phase 1 interventional study registered as NCT06561685 by Eli Lilly and Company, with 340 participants planned, started 2024-09-19. Conditions recorded: Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer and SMARCA4-Deficient Tumor. Interventions recorded: LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel and Nab paclitaxel.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06561685","url":"https://clinicaltrials.gov/study/NCT06561685"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["fhd-909"],"companies":["foghorn-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06561685","phase":"1","setting":"An Open-label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies With SMARCA4/BRG1 Alterations","sponsor":"Eli Lilly and Company","enrolled":340,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06561685/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"fhd-909","kind":"drug","name":"FHD-909","route":"/drugs/fhd-909/"}],"company":[{"id":"foghorn-therapeutics","kind":"company","name":"Foghorn Therapeutics","route":"/companies/foghorn-therapeutics/"}]}}